Evidence map›Paper›PMID 37648971›Full record

ArticleBMC pregnancy and childbirth2023

Serologic evolution and follow-up to IgG antibodies of infants born to mothers with gestational COVID.

Sara Vigil-Vázquez, Ángela Manzanares, Alicia Hernanz-Lobo, Itziar Carrasco-García, Clara Zamora Del Pozo, Alba Pérez-Pérez, Elena María Rincón-López, Begoña Santiago-García, María Del Pilar Pintado-Recarte, Roberto Alonso-Fernández and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC pregnancy and childbirth, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Sara Vigil-VázquezDepartment of Neonatology, Hospital General Universitario Gregorio Marañón, Calle O'Donnel 48, Madrid, 28009, Spain. saravv90@gmail.com.
Ángela ManzanaresPediatric Infectious Disease Unit, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
Alicia Hernanz-LoboPediatric Infectious Disease Unit, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
Itziar Carrasco-GarcíaPediatric Infectious Disease Unit, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
Clara Zamora Del PozoDepartment of Obstetrics and Gynecology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Alba Pérez-PérezDepartment of Neonatology, Hospital General Universitario Gregorio Marañón, Calle O'Donnel 48, Madrid, 28009, Spain.
Elena María Rincón-LópezPediatric Infectious Disease Unit, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
Begoña Santiago-GarcíaPediatric Infectious Disease Unit, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
María Del Pilar Pintado-RecarteDepartment of Obstetrics and Gynecology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Roberto Alonso-FernándezDepartment of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Manuel Sánchez-LunaDepartment of Neonatology, Hospital General Universitario Gregorio Marañón, Calle O'Donnel 48, Madrid, 28009, Spain.
María Luisa Navarro-GómezPediatric Infectious Disease Unit, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
Hospital General Universitario Gregorio Marañón · ESInstituto de Salud Carlos III · ESUniversidad Complutense de Madrid · ES

Funding

Instituto de Salud Carlos III Grant n° COV20/00808
6 · The paper itself

Abstract

backgroundIt is known that SARS-CoV-2 antibodies from pregnant women with SARS-CoV-2 infection during pregnancy cross the placenta but the duration and the protective effect of these antibodies in infants is scarce.

methodsThis prospective study included mothers with SARS-COV-2 infection during pregnancy and their infants from April 2020 to March 2021. IgG antibodies to SARS-CoV-2 spike protein were performed on women and infants at birth and at two and six months during follow-up. Anthropometrical measures and physical and neurological examinations and a clinical history of symptoms and COVID-19 diagnosis were collected. Simple linear regression was performed to compare categorical and continuous variables. To compare the mother's and infant's antibody titers evolution, a mixed linear regression model was used. A predictive model of newborn antibody titers at birth has been established by means of simple stepwise linear regression.

results51 mother-infant couples were included. 45 (90%) of the mothers and 44 (86.3%) of the newborns had a positive serology al birth. These antibodies were progressively decreasing and were positive in 34 (66.7%) and 7 (13.7%) of infants at 2 and 6 months, respectively. IgG titers of newborns at birth were related to mothers' titers, with a positive moderate correlation (Pearson's correlation coefficient: 0.82, p < 0,001). Fetal/maternal antibodies placental transference rate was 1.3 (IQR: 0.7-2.2). The maternal IgG titers at delivery and the type of maternal infection (acute, recent, or past infection) was significantly related with infants' antibody titers at birth. No other epidemiological or clinical factors were related to antibodies titers. Neurodevelopment, psychomotor development, and growth were normal in 94.2% of infants in the third follow-up visit. No infants had a COVID-19 diagnosis during the follow-up period.

conclusionsTransplacental transfer of maternal antibodies is high in newborns from mothers with recent or past infection at delivery, but these antibodies decrease after the first months of life. Infant's IgG titers were related to maternal IgG titers at delivery. Further studies are needed to learn about the protective role of maternal antibodies in infants.

Indexed as

COVID-19Pregnancy Complications, InfectiousCOVID-19 TestingFemaleFollow-Up StudiesHumansImmunoglobulin GInfant, NewbornMothersPlacentaPregnancyProspective StudiesSARS-CoV-2Spike Glycoprotein, CoronavirusImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Antibodies titersAntibodies transplacental transferGestational COVIDNeonatal SARS-COV-2 infectionSerological test

Identifiers

PMID37648971
PMCPMC10469412
OpenAlexW4386304348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.